Annexin Pharmaceuticals AB (publ)

Annexin Pharmaceuticals AB (publ) is a biotechnology firm dedicated to developing innovative therapeutic agents aimed at addressing a wide range of cardiovascular conditions. A cornerstone of their pipeline is ANXV, a specifically engineered human recombinant protein. This protein, which utilizes Annexin A5, is designed to both protect and repair blood vessels while actively mitigating inflammatory responses. The company was established in 2014 and maintains its headquarters in Stockholm, Sweden.